Fig. 3From: Therapeutic drug monitoring of anti-TNF drugs: an overview of applicability in daily clinical practice in the era of treatment with biologics in juvenile idiopathic arthritis (JIA)Dose vs. infliximab concentration. Red: ADA-positive patients. Blue: frequency every 4 weeks. Yellow: frequency every 6 weeks. Green: every 8 weeksBack to article page